The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
|Videos|April 27, 2011
Dr. Edith Perez Discusses Her Ongoing Research
Author(s)Edith A. Perez, MD,
Advertisement
Edith A. Perez, MD, director of the Breast Program and professor of medicine at the Mayo Clinic discusses her ongoing research.
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The top 5 OncLive TV videos of the week.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
2
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
3
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
4
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
5